Myriad Genetics Q2 revenue $212M (+15% YoY); raises FY2024 guidance, adjusted EPS $0.05

MYRIAD GENETICS INC

2024-Q2 EPS reported -$0.69 revenue$413,700,000

Revenue $212M (+15% YoY); GAAP EPS $(0.41) vs $(1.42) YoY; adjusted EPS $0.05 vs $(0.08).
Raises FY2024 revenue guidance to $835-$845M (11-12% growth); adj EPS to $0.08-$0.12.
Prenatal rev +25%, Pharmacogenomics +22%, Hereditary Cancer +19%; Tumor profiling -9% YoY.
Cross-license with Personalis (PSNL) for MRD patents; GSK collaboration for HRD testing.
Long-term revenue growth target raised to 12% from prior; total test volume +9% to 389K.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.